- Tailored to your requirements
- Deadlines from 3 hours
- Easy Refund Policy
The treatment line for depression continues to develop with emerging enthusiasm for other approaches aside from traditional pharmacotherapy and counseling. One of the approaches highly in use and getting a lot of interest is psilocybin-assisted therapy, which includes psilocybin use in combination with psycho-therapeutic support. This annotated bibliography is intended to examine the impact of psilocybin-assisted therapy in the treatment of depression through a selection of recent research articles on the matter. By summarizing, analyzing, and putting the results of these studies together, this paper will explain the utility of psilocybin-assisted therapy in managing depression and consider its relevance, credibility, and implications for future research and clinical practices.
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
Put your paper in expert hands
Get a custom essay written to your exact requirements – researched, structured, and delivered on time.
Write my essayThis randomized clinical trial, published in JAMA Psychiatry, investigates the effectiveness of psilocybin therapy in people with Major Depressive Disorder (MDD). A detailed study of 27 participants aged between 21 and 75 is carried out at the Center for Psychedelic and Consciousness Research. The study, spanning approximately between August 2017 and April 2019, analyzes the effect of intravenous dosing of a standardized psychedelic compound followed by psychotherapy support sessions. These results indicate a significant difference in the depression level between the treatment-as-usual group and the group that gets the immediate supply of antidepressants. The research findings indicated quick and continuous ant-depressive effects of psilocybin-assisted treatment, with 71% of participants still showing clinically meaningful responses at the 4-week follow-up. This study has significant relevance in that it searches for new therapeutic approaches in the treatment of MDD, a widespread disease, and a well-known mental disability course. The study’s credibility is also increased through rigorous methods such as randomized controlled trials, having blinded clinician assessments, and adhering to ethical standards. Moreover, it reflects that it has been lodged in a well-known journal, with JAMA Psychiatry confirming its scientific credibility and consequence in psychiatry and mental health studies.
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. https://doi.org/10.1177/02698811211073759
This investigation did a prospective 12-month follow-up study to examine the long-term efficacy and safety of psilocybin-assisted treatment in patients with major depressive disorder (MDD). The protocol was an individual with moderate to severe MDD inclusion criteria with two high doses of psilocybin in a supportive psycho-therapeutic setting. The study also found that all 24 participants showed a significant reduction in the scores of the severity of depression in their 12-month follow-up assessments, with more than 75% treatment response and remission rates at the 1-month mark, 6-month mark, and 3-month mark, respectively. Notably, none of the adverse events related to psychedelics, which were reported during the long-term follow-up period, were severe, but the medication demonstrated its safety profile. The study highlighted that participant-rated personal significance, spiritual experience, and mystic experience were all predictors of improved well-being at 12 months. This research, therefore, indicates that therapy assisted by psilocybin may have a long-term benefit for some patients with MDD. The study is relevant as it contributes to the knowledge about the role of psilocybin-assisted therapy in the novel treatment of MDD, focusing on long-term outcomes. Its credibility is based on randomized, controlled trial design, follow-up over time, incidental data collection, and observed safety profile, supporting researchers for the absolute validity of the study.
Pearson, C., Siegel, J., & Gold, J. A. (2022). Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the Neurological Sciences, 434, 120096. https://doi.org/10.1016/j.jns.2021.120096
This study provides an up-to-date overview of the next-generation studies on psilocybin-assisted psychotherapy for depression, including its history and fresh discoveries in the field. The discussion opens with a statement on the necessity of the search for better methods to deal with this growing disease since existing ones are not always compelling enough. It explains psilocybin’s history, pharmacology, and the mechanisms that might help its antidepressant work by being quick-acting. In addition, the article supplies a detailed look at the studies that aim to establish the effectiveness and safety of psilocybin for major depressive disorder, resulting in considerable positive data. Additionally, the authors frame these findings within the general framework of depression treatment, bringing up the notion of the challenges and limitations to the use of psychedelics in clinical setups. The significance of this review is in the detailed coverage of both historical and contemporary research on psilocybin, which serves to explore its alternative curative approach to depression. The review’s credibility is enhanced by its publication in the prestigious and top-tier journal of the Neurological Sciences, which is rigorously peer-reviewed, and the authors’ expertise in psychiatry and psychedelics research.
Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., & Young, A. (2021). Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomized, placebo-controlled feasibility trial. BMJ Open, 11(12), e056091. https://doi.org/10.1136/bmjopen-2021-056091
The study presents a protocol for the “Psilocybin-Assisted Therapy for the Treatment of Resistant Major Depressive Disorder (PsiDeR)” trial, which will determine the ability of psilocybin-assisted therapy to help those individuals diagnosed with major depressive disorder (MDD) that has shown to be resistant to conventional techniques. The trial is a randomized parallel group double-anonymized, placebo-controlled one recruiting up to 60 patients in London, UK, whose MDD has not responded to non-pharmacological and pharmacological interventions with at least two successful ones. Participants are assigned either an intervention or a placebo, providing a whopping 25mg psilocybin ingestion accompanied by psychological therapy. The primary outcome index is the Montgomery Asberg Depression Rating Scale (MADRS), with the sub-outcomes being other than depression scales, anxiety measurements, and the patient’s quality of life evaluation. This research involves the technology of neuroimaging and omics data collection for mechanistic and biomarker analyses and includes a double-masked, placebo-controlled trial among the other candidate clinical trials. This paper looks at the research history of psychedelic studies, the recent trials being conducted, as well as the significance of a blend of placebo-controlled studies that have been introduced. The relevance of this research is the fact that we now have a way forward on the issue of treatment resistance in depression, which may be an essential breakthrough. The work’s credibility is established by its ethical approvals, precise methodology, and faithful application of standard clinical trial processes.
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology, 37(7), 026988112311548. https://doi.org/10.1177/02698811231154852
The study used an experimental, placebo-controlled, internal cross-over design to evaluate the efficacy of psilocybin-assisted therapy on major depressive disorder (MDD). The research subjects, who were diagnosed with moderate to severe episodes of MDD, were randomly allocated to either a placebo or a segmented course of psychotherapy. Also, no special measures were taken to waylay maneuvers that might compromise the credibility of the research. The result revealed that depression and anxiety had declined after placebo and psilocybin had been administered, which were marked by larger effect sizes in the psilocybin treatment. Furthermore, psilocybin resulted in a high response and remission rate, showing a lifetime antidepressant effect beyond those two months. The study presents the fact that psilocybin could be effective for MDD treatment. However, they point to the wisdom of the fact that all the therapy components and expectancy effects should be taken into account in the actual psychedelic-assisted therapy research. The results of this study are essential for clinicians and researchers seeking new options for managing MDD. The study provides invaluable data on the immediate and enduring psycho-therapeutic effects of psilocybin, calling for more studies to establish its efficacy and the source of its therapeutic effect. The study’s credibility is supported by its publication in the Journal of Psychopharmacology, a top-class peer-reviewed journal, and the sophistication of its methodology, which involved the use of a placebo control and high blinding levels.
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809
This research trials the effectiveness of a single, moderate dose of psilocybin as a remedy to major depressive disorder (MDD) under the conditions of a placebo-controlled, double-blind, randomized clinical trial. The study aimed to fill this gap in the literature by comparing the effects of low-dose psilocybin micro-dosing to placebo. For fifty-two patients diagnosed with MDD, the treatment course consisted of either psilocybin in combination with psychological support or a placebo. The measurements were carried out by applying MADRS and BDI scores key markers. The findings suggest highly reduced depressive symptoms in the treatment group that received psilocybin when compared with the placebo group, where 54% of subjects reached the remitting criteria. This study suggests the possibility of psilocybin working rapidly for MDD, bringing attention to the need for bigger, multi-center studies with longer follow-up periods to enhance this new mode of treatment. The study’s credibility is reinforced by the journal EClinicalMedicine, which publishes peer-reviewed publications and is supported by well-known institutions, such as the Swiss National Science Foundation and the Heffter Research Institute.
Offload drafts to field expert
Our writers can refine your work for better clarity, flow, and higher originality in 3+ hours.
Match with writerReferences
- Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
- Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. https://doi.org/10.1177/02698811211073759
- Pearson, C., Siegel, J., & Gold, J. A. (2022). Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the Neurological Sciences, 434, 120096. https://doi.org/10.1016/j.jns.2021.120096
- Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., & Young, A. (2021). Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. BMJ Open, 11(12), e056091. https://doi.org/10.1136/bmjopen-2021-056091
- Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology, 37(7), 026988112311548. https://doi.org/10.1177/02698811231154852
- von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. https://doi.org/10.1016/j.eclinm.2022.101809